Imfinzi 120 mg/2.4 mL injection Images
Generic Name: durvalumab
This medication has been identified as Imfinzi 120 mg/2.4 mL injection. It is supplied by AstraZeneca.
Imfinzi is used in the treatment of Small Cell Lung Cancer; Non Small Cell Lung Cancer; Biliary Tract Tumor; Hepatocellular Carcinoma; Bladder Cancer and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Imfinzi 120 mg/2.4 mL injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Imfinzi
- Generic Name
- durvalumab
- Strength
- 120 mg/2.4 mL injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AstraZeneca
- National Drug Code (NDC)
- 00310-4500
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Trexall
Trexall is used for acute lymphoblastic leukemia, acute lymphocytic leukemia, breast cancer ...
Rasuvo
Rasuvo is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
More about Imfinzi (durvalumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.